Cipaglucosidase Alfa

4 trials 3 recruiting AGastroenterology Orphan designation

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

3 Recruiting

1 Completed trials

2 Sponsors

10 Countries

Phase III

Phase IV

Phase III: 3 Phase IV: 1

Sponsors using this IMP

Amicus Therapeutics Inc. 3 Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) 1

All trials

4 total

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of cipaglucosidase alfa/miglustat in both E… Recruiting

2022-501095-25-01 Phase III 5 countries Amicus Therapeutics Inc.
Study to evaluate the safety and efficacy of Cipaglucosidase Alfa and Miglustat in pediatric subjects with late-onset Pompe disease Recruiting

2022-502547-36-00 Phase III 2 countries Amicus Therapeutics Inc.
Treatment frequency Reduction In POmpe disease (TRIPO-Study) Recruiting

2024-514255-15-01 Phase IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
A study investigating the long-term safety and efficacy of intravenous (IV) ATB200 when Co-administrated with oral AT2221 in adult subjects … Ended

2023-505170-15-00 Phase III 9 countries Amicus Therapeutics Inc.

Showing 1–4 of 4 trials

← All drugs A–Z